Abstract

The aim of the present work is to Formulate and Evaluate controlled release of Diltiazem matrix tablets used for treat high blood pressure and control angina.   Development of CR Diltiazem is proposed considering the adverse event profile and high fluctuation index of Diltiazem observed with IR dosage forms. In the present work, attempts were made to formulate and evaluate controlled release of matrix tablets of Diltiazem.  Diltiazem was subjected to preformulation studies, based on the results obtained Diltiazem controlled release tablets were successfully formulated. Formulations prepared by wet granulation using HPMC and carbopol 934 as control release polymers and 5% W/W of povidone in isopropyl alcohol as binder solution have showed desired in vitro release. Set of trials were formulated for which Diltiazem evaluated parameters (bulk density, tapped density, compressibility index, hausner’s ratio, weight, thickness, hardness) were found to lie within the specifications. Dissolution study was performed in USP type II apparatus at 100 RPM in pH 6.8 phosphate phosphate buffer.